SMYD2-IN-1, with the CAS number 2023788-96-5, is a small molecule inhibitor specifically designed to target the SMYD2 (SET and MYND domain-containing protein 2) enzyme, which plays a significant role in various biological processes, including gene regulation and cancer progression. This compound is characterized by its ability to selectively inhibit the methyltransferase activity of SMYD2, thereby interfering with its function in histone modification and potentially altering the epigenetic landscape of cancer cells. SMYD2-IN-1 has been studied for its therapeutic potential in various cancer types, particularly those where SMYD2 is overexpressed or aberrantly activated. The compound's efficacy and specificity make it a valuable tool in cancer research, providing insights into the role of methylation in tumor biology. Additionally, its chemical structure and properties are designed to optimize bioavailability and minimize off-target effects, which are critical factors in drug development. Further studies are ongoing to fully elucidate its pharmacokinetics, pharmacodynamics, and potential clinical applications.

SMYD2-IN-1

2023788-96-5: SMYD2-IN-1, with the CAS number 2023788-96-5, is a small molecule inhibitor specifically designed to target the SMYD2 (SET and MYND domain-containing protein 2) enzyme, which plays a significant role in various biological processes, including gene regulation and cancer progression. This compound is characterized by its ability to selectively inhibit the methyltransferase activity of SMYD2, thereby interfering with its function in histone modification and potentially altering the epigenetic landscape of cancer cells. SMYD2-IN-1 has been studied for its therapeutic potential in various cancer types, particularly those where SMYD2 is overexpressed or aberrantly activated. The compound's efficacy and specificity make it a valuable tool in cancer research, providing insights into the role of methylation in tumor biology. Additionally, its chemical structure and properties are designed to optimize bioavailability and minimize off-target effects, which are critical factors in drug development. Further studies are ongoing to fully elucidate its pharmacokinetics, pharmacodynamics, and potential clinical applications.

<p>SMYD2-IN-1 is an inhibitor of SMYD2 (IC50 of 4.45 nM).</p>

CAS 2023788-96-5

SMYD2-IN-1

SMYD2-IN-1

Ref: TM-T12939